Bristol-Myers Squibb, PsiOxus Therapeutics Announce Immuno-Oncology Clinical Partnership to Evaluate the Combination of Opdivo and Enadenotucirev; Bristol-Myers To Make One-Time Payment Of $10M To PsiOxus